Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.45 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.45 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.45 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | GPBAR1 | Q8TDU6 | 5/20 | 0.43 |
| ▸ | HPGD | P15428 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | LIPE | Q05469 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12550518 | 0.91 | POLB (0.50) | ALDH1A1POLBTDP1TSHRCHRNB2 | |
| SCHEMBL21305532 | 0.89 | SMN1; SMN2 (0.48) | ALDH1A1POLBTDP1TSHRCHRNB2 | |
| SCHEMBL11176346 | 0.82 | ALDH1A1 (0.43) | ALDH1A1POLBTDP1TSHRCHRNB2 | |
| SCHEMBL16435030 | 0.81 | ALDH1A1 (0.46) | ALDH1A1POLBTDP1TSHRCHRNB2 | |
| SCHEMBL2095575 | 0.80 | ALDH1A1 (0.48) | ALDH1A1POLBTDP1TSHRCHRNB2 | |
| SCHEMBL8986913 | 0.80 | ALDH1A1 (0.48) | ALDH1A1POLBTDP1TSHRCHRNB2 | |
| SCHEMBL692996 | 0.80 | ALDH1A1 (0.48) | ALDH1A1POLBTDP1TSHRCHRNB2 | |
| SCHEMBL198522 | 0.80 | FSCN1 (0.55) | ALDH1A1POLBTDP1TSHRCHRNB2 | |
| SCHEMBL11046065 | 0.80 | ALDH1A1 (0.50) | ALDH1A1TSHRMAPTSMN1; SMN2GPBAR1 | |
| SCHEMBL9254666 | 0.80 | APP (0.42) | ALDH1A1MAPTSMN1; SMN2GPBAR1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113896861-A | Dicyandiamide cured epoxy resin suitable for out-of-tank molding and preparation method thereof | 中航复合材料有限责任公司 | 2022-01-07 | — | — | CN | claimed |
| US-RE49686-E1 | Nitrogen-containing heterocyclic compound and use of same | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-10-10 | — | — | US | disclosed |
| US-RE49686-E1 | Nitrogen-containing heterocyclic compound and use of same | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-10-10 | — | — | US | disclosed |
| CN-113896861-A | Dicyandiamide cured epoxy resin suitable for out-of-tank molding and preparation method thereof | 中航复合材料有限责任公司 | 2022-01-07 | — | — | CN | disclosed |
| CN-112226039-A | Resin matrix for LDS (laser direct structuring) process, preparation method and prepreg | 江苏澳盛复合材料科技有限公司 | 2021-01-15 | — | — | CN | disclosed |
| US-RE48334-E1 | Nitrogen-containing heterocyclic compound and use of same | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2020-12-01 | — | — | US | disclosed |
| US-20110178060-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND AND USE OF SAME | TAKEDA PHARMACEUTICAL COMPANY LIMITED | 2011-07-21 | — | — | US | disclosed |
| US-20110178060-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND AND USE OF SAME | TAKEDA PHARMACEUTICAL COMPANY LIMITED | 2011-07-21 | — | — | US | disclosed |
| EP-2336105-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND AND USE OF SAME | Takeda Pharmaceutical Company Limited (JP) | 2011-06-22 | — | — | EP | disclosed |
| WO-2010032856-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND AND USE OF SAME | 武田薬品工業株式会社 (JP) | 2010-03-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110178060-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND AND USE OF SAME | NTSR2, BDKRB1, AVPR1B | ALDH1A1 3648/4885POLB 3271/4885TDP1 4445/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.